Cellular delivery of trophic factors for the treatment of Huntington's disease: Is neuroprotection possible?

Progress in Brain Research

Volumn 127, Issue , 2000, Pages 413-430

  Kordower, Jeffrey H ^a   Isacson, Ole ^b   Leventhal, Liza ^a   Emerich, Dwaine F ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b MCLEAN HOSPITAL   (United States)

^c ALKERMES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 NITROPROPIONIC ACID; 4 AMINOBUTYRIC ACID; 7 NITROINDAZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; CILIARY NEUROTROPHIC FACTOR; GLUTAMATE RECEPTOR; MESSENGER RNA; NERVE GROWTH FACTOR; NEUROTOXIN; NEUROTROPHIN 3; NEUROTROPHIN 4; NITRIC OXIDE SYNTHASE INHIBITOR; SOMATOSTATIN; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL MODEL; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; DEGENERATIVE DISEASE; FETAL TISSUE TRANSPLANTATION; GENE EXPRESSION; GENE THERAPY; GENETIC DISORDER; HUNTINGTON CHOREA; NEURAL TRANSPLANTATION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL THERAPY; BRAIN TRANSPLANTATION; CELL CULTURE; DISEASE MODEL; DRUG DELIVERY SYSTEM; GRAFT SURVIVAL; HUMAN; METHODOLOGY; NEOSTRIATUM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSPLANTATION;

ANIMALS; BRAIN TISSUE TRANSPLANTATION; CELLS, CULTURED; CILIARY NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GRAFT SURVIVAL; HUMANS; HUNTINGTON DISEASE; NEOSTRIATUM; NERVE GROWTH FACTOR; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; TISSUE THERAPY;

EID: 0034565845     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(00)27020-9     Document Type: Article

References (85)

1. Albin, R.L. and Greenamyre, J.T. (1992) Alternative excitotoxic hypotheses. Neurology, 42: 733-738.
2. Albin, R.L., Young, A.B., Penney, J.B., Handelin, B., Balfour, R., Anderson, K.D., Markel, D.S., Tourtellotte, W.W. and Reiner, A. (1990) Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease [see comments]. N. Engl. J. Med., 322: 1293-1298.
3. Albin, R.L., Reiner, A., Anderson, K.D., Dure, L.S., Handelin, B., Balfour, R., Whetsell, W.O.J., Penney, J.B. and Young, A.B. (1992) Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Ann. Neurol., 31: 425-430.
4. Anderson, K.D., Panayotatos, N., Corcoran, T.L., Lindsay, R.M. and Wiegand, S.J. (1996) Ciliary neurotrophic factor protects striatal output neurons in an animal model of Huntington disease. Proc. Natl. Acad. Sci. USA, 93: 7346-7351.
5. Araujo, D.M. and Hilt, D.C. (1997) Glial cell line-derived neurotrophic factor attenuates the excitotoxin-induced behavioral and neurochemical deficits in a rodent model of Huntington's disease. Neuroscience, 81: 1099-1110.
6. Araujo, D.M. and Hilt, D.C. (1998) Glial cell line-derived neurotrophic factor attenuates the locomotor hypofunction and striatonigral neurochemical deficits induced by chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid. Neuroscience, 82: 117-127.
7. Ashizawa, T., Wong, L.J., Richards, C.S., Caskey, C.T. and Jankovic, J. (1994) CAG repeat size and clinical presentation in Huntington's disease. Neurology, 44: 1137-1143.
8. Bamford, K.A., Caine, E.D., Kido, D.K., Plassche, W.M. and Shoulson, I. (1989) Clinical-pathologic correlation in Huntington's disease: A neuropsychological and computed tomography study. Neurology, 39: 796-801.
9. Beal, M.F., Kowall, N.W., Ellison, D.W., Mazurek, M.F., Swartz, K.J. and Martin, J.B. (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature, 321: 168-171.
10. Beal, M.F., Mazurek, M.F., Ellison, D.W., Swartz, K.J., Mcgarvey, U., Bird, E.D. and Martin, J.B. (1988) Somatostatin and neuropeptide Y concentrations in pathologically graded cases of Huntington's disease. Ann. Neurol., 23: 562-569.
11. Beal, M.F., Brouillet, E., Jenkins, B.G., Ferrante, R.J., Kowall, N.W., Miller, J.M., Storey, E., Srivastava, R., Rosen, B.R. and Hyman, B.T. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci., 13: 4181-4192.
12. Björklund, A., Campbell, K., Sirinathsinghji, D.J., Fricker, R.A. and Dunnett, S.B. (1994) Functional capacity of striatal transplants in the rat Huntington model. In: S.B. Dunnett and A. Björklund (Eds.), Functional Neural Transplantation. Raven Press, New York, pp. 157-195.
13. Block, F., Kunkel, M. and Schwarz, M. (1993) Quinolinic acid lesion of the striatum induces impairment in spatial learning and motor performance in rats. Neurosci. Lett., 149: 126-128.
14. Brouillet, E., Menetrat, H., Ouary, S., Altairac, S., Poyot, T., Mittoux, V. and Hantraye, P. (1998) Major species differences in the behavioral and neuropathological deficits observed in rats following chronic 3-nitropropionate treatment: Implications for modelling Huntington's disease in rodents. Soc. Neurosci. Abstr., 24: 970.
15. Calne, D.B. and Langston, J.W. (1983) Aetiology of Parkinson's disease. Lancet, 2: 1457-1459.
16. Clatterbuck, R.E., Price, D.L. and Koliatsos, V.E. (1993) Ciliary neurotrophic factor prevents retrograde neuronal death in the adult central nervous system. Proc. Natl. Acad. Sci. USA, 90: 2222-2226.
17. Conneally, P.M. (1984) Huntington disease: Genetics and epidemiology. Am. J. Hum. Genet., 36: 506-526.
18. Coyle, J.T. and Schwarz, R. (1976) Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature, 263: 244-246.
19. Davies, S.W. and Beardsall, K. (1992) Nerve growth factor selectively prevents excitotoxin induced degeneration of striatal cholinergic neurones. Neurosci. Lett., 140: 161-164.
20. DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277: 1990-1993.
21. Emerich, D.F. and Sanberg, P.R. (1992) Animal models in Huntington's disease. In: A.A. Boulton, G.B. Baker and R.F. Butterworth (Eds.), Neuronmethods Vol. 17, Humana Press, Totowa, NJ, pp. 65-134.
22. Emerich, D.F., Hammang, J.P., Baetge, E.E. and Winn, S.R. (1994) Implantation of polymer-encapsulated human nerve growth factor-secreting fibroblasts attenuates the behavioral and neuropathological consequences of quinolinic acid injections into rodent striatum. Exp. Neurol., 130: 141-150.
23. Emerich, D.F., Lindner, M.D., Winn, S.R., Chen, E.Y., Frydel, B.R. and Kordower, J.H. (1996) Implants of encapsulated human CNTF-producing fibroblasts prevent behavioral deficits and striatal degeneration in a rodent model of Huntington's disease. J. Neurosci., 16: 5168-5181.
24. Emerich, D.F., Cain, C.K., Greco, C., Saydoff, J.A., Hu, Z.Y., Liu, H. and Lindner, M.D. (1997a) Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington's disease. Cell Transplant., 6: 249-266.
25. Emerich, D.F., Winn, S.R., Hantraye, P.M., Peschanski, M., Chen, E.Y., Chu, Y., Mcdermott, P., Baetge, E.E. and Kordower, J.H. (1997b) Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature, 386: 395-399.
26. Emerich, D.F., Bruhn, S., Chu, Y. and Kordower, J.H. (1998) Cellular delivery of CNTF, but not NT-4/5 prevents degeneration of striatal neurons in a rodent model of Huntington's disease. Cell Transplant., 7: 213-225.
27. Farrer, L.A. and Conneally, P.M. (1985) A genetic model for age at onset in Huntington disease. Am. J. Hum. Genet., 37: 350-357.
28. Ferrante, R.J., Kowall, N.W., Beal, M.F., Richardson, E.P.J., Bird, E.D. and Martin, J.B. (1985) Selective sparing of a class of striatal neurons in Huntington's disease. Science, 230: 561-563.
29. Ferrante, R.J., Beal, M.F., Kowall, N.W., Richardson, E.P.J. and Martin, J.B. (1987) Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Res., 411: 162-166.
30. Freese, A., Finklestein, S.P. and Difiglia, M. (1992) Basic fibroblast growth factor protects striatal neurons in vitro from NMDA-receptor mediated excitotoxicity. Brain Res., 575: 351-355.
31. Frim, D.M., Simpson, J., Uhler, T.A., Short, M.P., Bossi, S.R., Breakfield, X.O. and Isacson, O. (1993a) Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J. Neurosci. Res., 35: 452-458.
32. Frim, D.M., Short, M.P., Rosenberg, W.S., Simpson, J., Breakfield, X.O. and Isacson, O. (1993b) Local protective effects of nerve growth factor-secreting fibroblasts against excitotoxic lesions in the rat striatum [see comments]. J. Neurosurg., 78: 267-273.
33. Frim, D.M., Uhler, T.A., Short, M.P., Ezzedine, Z.D., Klagsbrun, M., Breakefield, X.O. and Isacson, O. (1993c) Effects of biologically delivered NGF, BDNF and bFGF on striatal excitotoxic lesions. Neuroreport, 4: 367-370.
34. Frim, D.M., Yee, W.M. and Isacson. O. (1993d) NGF reduces striatal excitotoxic neuronal loss without affecting concurrent neuronal stress. Neuroreport, 4: 655-658.
35. Frim, D.M., Wullner, U., Beal, M.F. and Isacson. O. (1994) Implanted NGF-producing fibroblasts induce catalase and modify ATP levels but do not affect glutamate receptor binding or NMDA receptor expression in the rat striatum. Exp. Neurol., 128: 172-180.
36. Gage, F.H., Batchelor, P., Chen, K.S., Chin, D., Higgins, G.A., Koh, S., Deputy, S., Rosenberg, M.B., Fischer, W. and Björklund, A. (1989) NGF receptor reexpression and NGF-mediated cholinergic neuronal hypertrophy in the damaged adult neostriatum. Neuron, 2: 1177-1184.
37. Galpern, W.R., Matthews, R.T., Beal, M.F. and Isacson, O. (1996) NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington's disease. Neuroreport, 7: 2639-2642.
38. Graveland, G.A., Williams, R.S. and Difiglia, M. (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science, 227: 770-773.
39. Greenamyre, J.T. and Shoulson, I. (1994) Huntington's disease. In: D. Calne (Ed.), Neurodegenerative Diseases. Saunders Press, Philadelphia, PA, pp. 685-704.
40. Hagg, T. and Varon, S. (1993) Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. Proc. Natl. Acad. Sci. USA, 90: 6315-6319.
41. Hagg, T., Quon, D., Higaki, J. and Varon, S. (1992) Ciliary neurotrophic factor prevents neuronal degeneration and promotes low affinity NGF receptor expression in the adult rat CNS. Neuron, 8: 145-158.
42. Hantraye, P., Riche, D., Maziere, M. and Isacson, O. (1992) Intrastriatal transplantation of cross-species fetal striatal cells reduces abnormal movements in a primate model of Huntington disease. Proc. Natl. Acad. Sci. USA, 89: 4187-4191.
43. Higgins, G.A., Koh, S., Chen, K.S. and Gage, F.H. (1989) NGF induction of NGF receptor gene expression and cholinergic neuronal hypertrophy within the basal forebrain of the adult rat. Neuron, 3: 247-256.
44. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72: 971-978.
45. Isacson, O. (1993) On neuronal health. Trends Neurosci., 16: 306-308.
46. Isacson, O., Brundin, P., Kelly, P.A., Gage, F.H. and Björklund, A. (1984) Functional neuronal replacement by grafted striatal neurones in the ibotenic acid-lesioned rat striatum. Nature, 311: 458-460.
47. Ischiropoulos, H., Zhu, L., Chen, J., Tsai, M., Martin, J.C., Smith, C.D. and Beckman, J.S. (1992) Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys., 298: 431-437.
48. Kordower, J.H. and Mufson, E.J. (1993) NGF receptor (p75)-immunoreactivity in the developing primate basal ganglia. J. Comp. Neurol., 327: 359-375.
49. Kordower, J.H., Chen, E.Y., Sladek, J.R.J. and Mufson, E.J. (1994a) trk-immunoreactivity in the monkey central nervous system: Forebrain. J. Comp. Neurol., 349: 20-35.
50. Kordower, J.H., Charles, V., Bayer, R., Bartus, R.T., Putney, S., Walus, L.R. and Friden, P.M. (1994b) Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc. Natl. Acad. Sci. USA, 91: 9077-9080.
51. Kordower, J.H., Chen, E.Y., Mufson, E.J., Winn, S.R. and Emerich, D.F. (1996) Intrastriatal implants of polymer encapsulated cells genetically modified to secrete human nerve growth factor: Trophic effects upon cholinergic and noncholinergic striatal neurons. Neuroscience, 72: 63-77.
52. Kordower, J.H., Chen, E.Y., Winkler. C., Fricker, R., Charles, V., Messing, A., Mufson, E.J., Wong, S.C., Rosenstein, J.M., Björklund, A., Emerich, D.F., Hammang, J. and Carpenter, M.K. (1997) Grafts of EGF-responsive neural stem cells derived from GFAP-hNGF transgenic mice: Trophic and tropic effects in a rodent model of Huntington's disease. J. Comp. Neurol., 387: 96-113.
53. Kowall, N.W., Ferrante, R.J. and Martin, J.B. (1987) Pattern of cell loss in Huntington's disease. Trends Neurosci., 10: 24-29.
54. Levi-Montalcini, R. and Angeletti, P.U. (1968) Nerve growth factor. Physiol. Rev., 48: 534-569.
55. Lindsay, R.M., Wiegand, S.J., Altar, C.A. and Distephano, P.S. (1994) Neurotrophic factors, from molecules to man. Trends Neurosci., 17: 182-190.
56. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S.W. and Bates, G.P. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87: 493-506.
57. Martin, J.B. and Gusella, J.F. (1986) Huntington's disease. Pathogenesis and management. N. Engl. J. Med., 315: 1267-1276.
58. Martinez, H.J., Dreyfus, C.F., Jonakait, G.M. and Black, I.B. (1985) Nerve growth factor promotes cholinergic development in brain striatal cultures. Proc. Natl. Acad. Sci. USA, 82: 7777-7781.
59. Martinez-Serrano, A. and Björklund, A. (1996) Protection of the neostriatum against excitotoxic damage by neurotrophin-producing, genetically modified neural stem cells. J. Neurosci., 16: 4604-4616.
60. Mittoux, V., Joseph, J.M., Conde, F., Palfi, S., Zurn, A., Dautry, C., Poyot, T., Peschanski, M., Aebischer, P. and Hantraye, P. (1998) Encapsulated CNTF-producing fibroblasts reverse motor and cognitive deficits and protect striatal neurons in a chronic primate model of Huntington's disease. Soc. Neurosci. Abstr., 24: 973.
61. Mizuno, K., Carnahan, J. and Nawa, H. (1994) Brain-derived neurotrophic factor promotes differentiation of striatal GABAergic neurons. Dev. Biol., 165: 243-256.
62. Mobley, W.C., Rutkowski, J.L., Tennekoon, G.I., Buchanan, K. and Johnston, M.V. (1985) Choline acetyltransferase activity in striatum of neonatal rats increased by nerve growth factor. Science, 229: 284-287.
63. Mufson, E.J. and Kordower, J.H. (1998) Nerve growth factor and its receptors in the primate forebrain: alterations in Alzheimer's disease and potential use in experimental therapeutics. In: M. Mattson (Ed.), Neuroprotective Signal Transduction. Humana Press, Totowa, NJ, pp. 23-59.
64. Nakao, N., Brundin, P., Funa, K., Lindvall, O. and Odin, P. (1995) Trophic and protective actions of brain-derived neurotrophic factor on striatal DARPP-32-containing neurons in vitro. Brain Res. Dev. Brain Res., 90: 92-101.
65. Nistico, G., Ciriolo, M.R., Fiskin, K., Iannone, M., De Martino, A. and Rotilio, G. (1992) NGF restores decrease in catalase activity and increases superoxide dismutase and glutathione peroxidase activity in the brain of aged rats. Free Radic. Biol. Med., 12: 177-181.
66. Palfi, S., Ferrante, R.J., Brouillet, E., Beal, M.F., Dolan, R., Guyot, M.C., Peschanski, M. and Hantraye, P. (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J. Neurosci., 16: 3019-3025.
67. Palfi, S., Conde, F., Riche, D., Brouillet, E., Dautry, C., Mittoux, V., Chibois, A., Peschanski, M. and Hantraye, P. (1998) Fetal striatal allografts reverse cognitive deficits in a primate model of Huntington disease. Nat. Med., 4: 963-966.
68. Pelleymounter, M.A., Cullen, M.J., Baker, M.B., Gollub, M. and Wellman, C. (1996) The effects of intrahippocampal BDNF and NGF on spatial learning in aged Long Evans rats. Mol. Chem. Neuropathol., 29: 211-226.
69. Perez-Navarro, E., Arenas, E., Reiriz, J., Calvo, N. and Alberch, J. (1996) Glial cell line-derived neurotrophic factor protects striatal calbindin-immunoreactive neurons from excitotoxic damage. Neuroscience, 75: 345-352.
70. Perez-Navarro, E., Arenas, E.S., Marco, S. and Alberch, J. (1999) Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo. Eur. J. Neurosci., 11: 241-249.
71. Rosas, H.D., Koroshetz, W.J., Jenkins, B.G., Chen, Y.I., Hayden, D.L., Beal, M.F. and Cudkowicz, M.E. (1999) Riluzole therapy in Huntington's disease. Mov. Disord., 140: 326-330.
72. Sanchez, I., Xu, C.J., Juo, P., Kakizaka, A., Blenis, J. and Yuan, J. (1999) Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron, 22: 623-633.
73. Schulz, J.B., Matthews, R.T., Jenkins, B.G., Ferrante, R.J., Siwek, D., Henshaw, D.R., Cipolloni, P.B., Mecocci, P., Kowall, N.W. and Rosen, B.R. (1995) Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. J. Neurosci., 15: 8419-8429.
74. Schumacher, J.M., Short, M.P., Hyman, B.T., Breakefield, X.O. and Isacson, O. (1991) Intracerebral implantation of nerve growth factor-producing fibroblasts protects striatum against neurotoxic levels of excitatory amino acids. Neuroscience, 45: 561-570.
75. Shannon, K.M. and Kordower, J.H. (1996) Neural transplantation for Huntington's disease: Experimental rationale and recommendations for clinical trials. Cell Transplant., 5: 339-352.
76. Simpson, J.R. and Isacson, O. (1993) Mitochondrial impairment reduces the threshold for in vivo NMDA-mediated neuronal death in the striatum. Exp. Neurol., 121: 57-64.
77. Sims, N.R., Bowen, D.M., Allen, S.J., Smith, C.C., Neary, D., Thomas, D.J. and Davison, A.N. (1983) Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem., 40: 503-509.
78. Sobreviela, T., Clary, D.O., Reichardt, L.F., Brandabur, M.M., Kordower, J.H. and Mufson, E.J. (1994) TrkA-immunoreactive profiles in the central nervous system: Colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J. Comp. Neurol., 350: 587-611.
79. Steininger, T.L., Wainer, B.H., Klein, R., Barbacid, M. and Palfrey, H.C. (1993) High-affinity nerve growth factor receptor (Trk) immunoreactivity is localized in cholinergic neurons of the basal forebrain and striatum in the adult rat brain. Brain. Res., 612: 330-335.
80. + pump may mediate the control of nerve cells by nerve growth factor. Trends Biol. Sci., 8: 22-25.
81. Venero, J.L., Beck, K.D. and Hefti, F. (1994) Intrastriatal infusion of nerve growth factor after quinolinic acid prevents reduction of cellular expression of choline acetyltransferase messenger RNA and trkA messenger RNA, but not glutamate decarboxylase messenger RNA. Neuroscience, 61: 257-268.
82. Ventimiglia, R., Mather, P.E., Jones, B.E., and Lindsay, R.M. (1995) The neurotrophins BDNF, NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of striatal neurons in vitro. Eur. J. Neurosci., 7: 213-222.
83. Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P.J. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44: 559-577.
84. Widmer, H.R. and Hefti, F. (1994) Neurotrophin-4/5 promotes survival and differentiation of rat striatal neurons developing in culture. Eur. J. Neurosci., 6: 1669-1679.
85. Winn, S.R., Lindner, M.D., Lee, A., Haggett, G., Francis, J.M. and Emerich, D.F. (1996) Polymer-encapsulated genetically modified cells continue to secrete human nerve growth factor for over one year in rat ventricles: Behavioral and anatomical consequences. Exp. Neurol., 140: 126-138.